Abstract 1779P
Background
Salvage radiotherapy (SRT) is one of the cornerstone for treatment of biochemical relapse (BR) after radical prostatectomy (RP). One randomized controlled trial suggested that next generation imaging (NGI) may have a significant impact on patients management in this scenario. Nonetheless, how to best manage oligometastatic patients identified by PSMA PET imaging requires additional investigation. PSICHE (NCT05022914) is a prospective multicentric trial aimed to test a [68Ga]Ga- PSMA-11 PET/CT imaging tailored strategy.
Methods
Patients affected by biochemical relapse post RP (defined as PSA >0.2 ng/ml, <1 ng/ml) underwent [68Ga]Ga-PSMA-11 PET/CT imaging. After staging, management was performed according to a pre-defined algorithm. Observation and re-staging at further PSA progression were proposed to patients with negative PSMA and previous postoperative RT. Prostate bed SRT was proposed to all patients with a negative staging or positive imaging within prostate bed. Stereotactic body radiotherapy (SBRT) to all sites of disease was used for all patients with pelvic nodal recurrence (nodal disease < 2 cm under aortic bifurcation) or oligometastatic disease. Androgen deprivation therapy +/- androgen receptor targeted agent was provided in case of widespread metastatic disease. In the present analysis, we report early biochemical analysis focusing on complete biochemical response (PSA ≤0.2 ng/ml) and biochemical response (PSA ≤50% if compared to baseline value before treatment). Gastrointestinal (GI) or genitourinary (GU) toxicity was assessed according to CTCAE v 4.0.
Results
Overall, 110 patients were included in the current analysis. At 3 months after treatment, complete biochemical response and biochemical response were detected in 45.4% and 53.6% of patients, respectively. Seven patients had G1 GI toxicity, GU toxicity was reported in 30 patients (only 3 G2 adverse events, overall). No G>2 toxicity was reported.
Conclusions
A PSMA targeted treatment strategy led to promising results and was well tolerated within a prospective multicentric trial.
Clinical trial identification
NCT05022914.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14